A practical reference on Preclinical research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-13 and is reviewed periodically as new material appears.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Marketed for research use in some regions. |
| Human clinical data | Limited or absent | Most evidence is from cell and animal studies. |
| Primary proposed pathway | HGF/c-Met signaling | Angiotensin IV-related activity also reported. |
| Common study models | Rodent neurons and behavioral tasks | Results may not translate directly to humans. |
| Key uncertainty | Bioavailability and brain exposure | Questions remain about absorption and target engagement. |
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
Research on dihexa has primarily used rodent models and cultured cells. Common endpoints include dendritic spine density, synaptic protein expression, and performance on maze or avoidance tasks. Some studies report improvements in cognitive measures after scopolamine-induced deficits or in aged animals. These findings are interesting but come from a small body of work, and independent laboratories have not consistently replicated all reported effects. Larger, preregistered studies would help clarify which results are robust.
Since its 2006 merger with Maytag, Whirlpool has closed many of its plants including Maytag's main plant in Newton, Iowa, as well as its existing plants in Evansville, Indiana and Fort Smith, Arkansas.
Researchers have found ways for pregnant women with gestational diabetes to reduce their complications with their current health, long-term effects, and fetal health with the help of exercise. Laredo-Aguilera, et al., and Dipla, et al., presented findings from systematic and meta-analyses that showed positive effects of resistance exercise or a combination of resistance and aerobic exercise. Aerobic and resistance training were found to control glucose, HgbA1c, and insulin levels in women with GDM. Not only is the mother's health affected, but also the fetus's. If GDM is not treated or is made worse, the child may suffer from macrosomia, impaired intrauterine growth, obstetric trauma, hyperbilirubinemia, hypoglycemia, or even infection. Pregnant women with GDM who are overweight or obese are at a greater risk of passing down these negative effects by 2.14-3.56 times. Benefits to resistance and aerobic exercise include a maternal decrease in cramps, lower back pain, edema, depression, urinary incontinence, duration of labor, constipation, and the number of c-sections. These benefits can affect the fetus by having a decreased body fat mass, improved stress tolerance, and advanced neurobehavioral maturation. In the article written by Laredo-Aguilera, et al., there were seven interventions and seven different countries that were used for research. Within all of the interventions, there were significant improvements in glucose concentration, reduced requirements of insulin injections, postprandial glucose level control, and glycemic control.
Human activities have affected stocks of many species of teleost, through overfishing, pollution and global warming. Among many recorded instances, overfishing caused the complete collapse of the Atlantic cod population off Newfoundland in 1992, leading to Canada's indefinite closure of the fishery. Pollution, especially in rivers and along coasts, has harmed teleosts as sewage, pesticides and herbicides have entered the water. Many pollutants, such as heavy metals, organochlorines, and carbamates interfere with teleost reproduction, often by disrupting their endocrine systems. In the roach, river pollution has caused the intersex condition, in which an individual's gonads contain both cells that can make male gametes (such as spermatogonia) and cells that can make female gametes (such as oogonia). Since endocrine disruption also affects humans, teleosts are used to indicate the presence of such chemicals in water. Water pollution caused local extinction of teleost populations in many northern European lakes in the second half of the twentieth century. The effects of climate change on teleosts could be powerful but are complex. For example, increased winter precipitation (rain and snow) could harm populations of freshwater fish in Norway, whereas warmer summers could increase growth of adult fish. In the oceans, teleosts may be able to cope with warming, as it is simply an extension of natural variation in climate. It is uncertain how ocean acidification, caused by rising carbon dioxide levels, might affect teleosts.
In clinical trials, refers to a drug (including a new drug, dose, combination, or route of administration) or procedure that has undergone basic laboratory testing and received approval from the U.S. Food and Drug Administration (FDA) to be tested in human subjects. A drug or procedure may be approved by the FDA for use in one disease or condition, but be considered investigational in other diseases or conditions. Also called experimental. (NCI) Investigational drug
=== North America === Soybeans were first introduced to North America from China in 1765, by Samuel Bowen, a former East India Company sailor who had visited China in conjunction with James Flint, the first Englishman legally permitted by the Chinese authorities to learn Chinese. The first "New World" soybean crop was grown on Skidaway Island, Georgia, in 1765 by Henry Yonge from seeds given him by Samuel Bowen. Bowen grew soy near Savannah, Georgia, possibly using funds from Flint, and made soy sauce for sale to England. Although soybean was introduced into North America in 1765, for the next 155 years, the crop was grown primarily for forage. In 1831, the first soy product "a few dozen India Soy" [sauce] arrived in Canada. Soybeans were probably first cultivated in Canada by 1855, and definitely in 1895 at Ontario Agricultural College. It was not until Lafayette Mendel and Thomas Burr Osborne showed that the nutritional value of soybean seeds could be increased by cooking, moisture or heat, that soy went from a farm animal feed to a human food. William Joseph Morse is considered the "father" of modern soybean agriculture in America. In 1910, he and Charles Piper began to popularize what was regarded as a relatively unknown Oriental peasant crop in America into a "golden bean", with the soybean becoming one of America's largest and most nutritious farm crops.
Sources: en.wikipedia.org
== Further information == Betz Laboratories (1976). Handbook of Industrial Water Conditioning (7th ed.). Betz Laboratories. Ion Exchangers (K. Dorfner, ed.), Walter de Gruyter, Berlin, 1991. C. E. Harland, Ion exchange: Theory and Practice, The Royal Society of Chemistry, Cambridge, 1994. Friedrich G. Helfferich (1962). Ion Exchange. Courier Dover Publications. ISBN 978-0-486-68784-1. {{cite book}}: ISBN / Date incompatibility (help) Kemmer, Frank N. (1979). The NALCO Water Handbook. McGraw-Hill. Ion exchange (D. Muraviev, V. Gorshkov, A. Warshawsky), M. Dekker, New York, 2000. A. A. Zagorodni, Ion Exchange Materials: Properties and Applications, Elsevier, Amsterdam, 2006. SenGupta, Arup K. (2017). Ion exchange in environmental processes: fundamentals, applications and sustainable technology. Hoboken, NJ. ISBN 978-1-119-42125-2. OCLC 1001290476.{{cite book}}: CS1 maint: location missing publisher (link) Dr., I., & Luqman, M. (2012). Ion Exchange Technology I : Theory and Materials. Springer Netherlands. Harland, C. E. (1994). Ion exchange : theory and practice (2nd ed.). The Royal Society of Chemistry.
Valerie Joy Beynon. For services to the community in Cobham, Surrey. Elizabeth Kay Billington. Chair, Kushti Bok and Vice-Chair, Dorset Council Gypsy Traveller Forum. For services to the Gypsy and Traveller Community in Dorset. William Archibald Bingham. Chair, Newcastle and Mourne Cancer Research Committee. For services to Cancer Research Fundraising in County Down. Chandra Shekhar Biyani. Consultant Urological Surgeon, Leeds Teaching Hospitals NHS Trust. For services to Medical Education. Reverend Christine Fiona Blackman. For services to the community in Reading, Berkshire. Derek John Bland. For services to the community in Northamptonshire. Roberta Vivian Lindsay Blyth. For services to the community in Roade, Northamptonshire. Winifred Patricia Bownes. Volunteer Coordinator, Cookstown Monday Club. For services to the community in Cookstown, County Tyrone. Mary Boyes. Cleaner, North Shore Academy, Stockton-on-Tees. For services to Education. John Robert Boyne-Aitken. For services to Heritage Crafts. Evelyn Lettita Bracey. For services to the community in Wantage, Oxfordshire. Paul Mark Brackley. Community First Responder, Oundle Community First Responders. For services to the community in Oundle and North Northamptonshire. Christopher Samuel Bradbury. For services to the community in Reedham, Norfolk. Moira Jeanette Brock. Founder and Principal, La Danse Fantastique. For services to Young People in Basildon, Essex. Anna Theresa Margaret Brown. For services to the NHS and to the community in the London Borough of Richmond-upon-Thames. Dennis Sydney Brown.
In 1968, 31 clinicians and laboratory scientists representing 15 organizations convened to establish a formal consensus process for standardization. In 1977, CLSI was accredited by the American National Standards Institute (ANSI) as a voluntary consensus standards organization. Around the same time, CLSI became the home of the National Reference System for the Clinical Laboratory (NRSCL), a collection of reference systems intended to improve the comparability of test results, consistent with medical practice needs. CLSI is a global association with over 1,500 member organizations and individual members, along with more than 2,000 volunteers. Until 2005, CLSI was known as the National Committee for Clinical Laboratory Standards (NCCLS).
Theriaca andromachi or Venice Treacle contained 64 ingredients. In addition to viper flesh and opium, it included cinnamon, agarikon and gum arabic. The ingredients were pulverized and reduced to an electuary with honey. The following ingredients for the theriac were taken from the Amsterdammer Apotheek (1683) and translated from the old Latin names into the Latin names now used where possible. Not all ingredients are known, and identifications and assignments below are tentative. Roots: Iris, Balsamorhiza deltoidea, Potentilla reptans (creeping cinquefoil), Rheum rhabarbarum (garden rhubarb), Zingiber officinale, Ulmus × hollandica 'Angustifolia' odorata, Gentiana, Meum athamanticum (spignel), Valeriana, Corydalis cava (hollowroot), glycyrrhiza Stems and barks: Cinnamomum verum (cinnamon), Cinnamomum aromaticum (cassia) Leaves: Teucrium scordium (water germander), Fraxinus excelsior, Clinopodium calamintha (lesser calamint), Marrubium vulgare (white or common horehound), Cymbopogon citratus (West-Indian lemongrass), Teucrium chamaedrys (wall germander), Cupressaceae, Laurus nobilis (bay laurel), Teucrium montanum (mountain germander), Cytinus hypocistis Flowers: Rosa, Crocus sativus, Lavandula stoechas (French lavender), Lavandula angustifolia (common or English lavender), Centaurea minoris (common centaury) Fruits and seeds: Brassica napus (rapeseed), Petroselinum (parsley), Nigella sativa, Pimpinella anisum (anise), Elettaria cardamomum, Foeniculum vulgare (fennel), Hypericum perforatum (St.
Sources: en.wikipedia.org
However, that 2006 review pre-dates recent data, which, although still too soon to be certain, suggest that the increase in childhood obesity in the US, the UK, and Sweden might be abating.3–5 A British longitudinal study has found that obesity restricted to childhood has minimal influence on adult outcomes at age 30. The study also found that, while obesity that continues into adulthood has little influence on men's outcomes, it makes women less likely to have ever been employed or to currently have a romantic partner. A 2017 National Bureau of Economic Research paper found that childhood obesity in the United States increases medical costs by $1,354 a year (in 2013 dollars).
=== Oxidation === Oxidation can occur both at sulfur, giving a thiophene S-oxide, as well as at the 2,3-double bond, giving the thiophene 2,3-epoxide, followed by subsequent NIH shift rearrangement. Oxidation with trifluoroperacetic acid demonstrates both reaction pathways. The major pathway forms the S-oxide as an intermediate, which undergoes subsequent Diels-Alder-type dimerisation and further oxidation, forming a mixture of sulfoxide and sulfone products with a combined yield of 83% (based on NMR evidence):
Hegseth had announced on 10 October the formation of a new counternarcotics joint task force, to operate in Latin America, the Western hemisphere, and the area of the United States Southern Command (USSOUTHCOM), to be headed by the II Marine Expeditionary Force, intended "to crush the cartels, stop the poison and keep America safe". On 13 November 2025, Hegseth announced the unveiling of Operation Southern Spear, led by Joint Task Force Southern Spear and using a fleet with robotics and autonomous systems to target Latin American drug trafficking, with operations to begin later in November. A US official told a reporter in November that Hegseth's 13 November unveiling was "a formal operation naming for what the Joint Task Force Southern Spear ... and Southcom have already been doing in theater".
Sources: en.wikipedia.org
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.
Preclinical research has focused on synaptic growth, cognitive performance in animals, and HGF/c-Met signaling. These are experimental findings, not established treatments.
Legality varies by country and intended use. It is commonly sold as a research chemical, and sales for human consumption may be restricted. Local regulations should be checked.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.